Showtime?, page-40

I expect theres two pipelines, B2B and B2C. B2B will be targeted at specific organisations and individuals early on, it won't rely on mass marketing and broad base Web sales - we won't see it as won't fit the buyer profile. It will be clinical trial orgs, large health providers etc, where deals will probably be in toward the millions. This is the most valuable segment for cdx at this stage... At least until the band and general market acceptance. Social campaigns and web ads are generally for B2C, which at 350 pop isn't worth chasing at this stage (limited production capacity, higher overhead for a small sale).